Here are the 10-Q quarterly reports from BioRegenx Inc (BRGX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BRGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRGX filings page.
BioRegenx, Inc. reported Q1 2026 net sales of $426,175, down 17% from $515,147 a year earlier as medical testing machine issues weighed on product demand. Gross profit was $348,288, with cost of sales falling 29%, but lower volumes still reduced gross profit versus Q1 2025.
Operating expenses declined sharply to $398,052 from $598,646, driven by reduced equity compensation, legal, accounting and professional fees. The company also recorded $100,435 of other income, largely from a write-off of accrued liabilities, partially offset by $77,086 of interest and financing costs.
Net loss narrowed to $26,415 from $266,854. Despite this improvement, BioRegenx ended the quarter with cash of $45,806, a stockholders’ deficit of $4,533,316, total liabilities of $4,870,386, and notes in default with aggregate principal of $522,500, leading management and auditors to conclude there is substantial doubt about its ability to continue as a going concern.
BioRegenx, Inc. reported Q3 results showing smaller losses and lean liquidity. Net sales were $507,755 versus $596,037 a year ago, with gross profit of $426,397. Operating expenses declined sharply due to the absence of prior-year amortization, narrowing loss from operations to $8,459 from $327,307. Net loss was $80,565 versus $394,860 in the prior-year quarter.
For the nine months, net sales were $1,468,872 versus $1,879,617, and net loss was $525,764 versus $4,653,446. Cash was $46,947 and stockholders’ deficit was $3,647,136 as of September 30, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern, noting $522,500 of notes in default and EIDL delinquencies of $400,000, both classified as current. Total liabilities were $4,814,900.
The company recorded a GlycoCheck sublicense with a three-year minimum royalty of $750,000, recognizing an intangible asset of $725,000 (net) and a $700,000 royalty liability. Common shares outstanding were 961,992,601 as of November 9, 2025.